文献速递介入泌尿生殖DSAUS

比较前列腺动脉栓塞术治疗良性前列腺增生相关下尿路症状所用栓塞颗粒

Comparing embolic particles for prostatic artery embolization to treat lower urinary tract symptoms in patients with benign prostatic hyperplasia.
PubMed 文献 · Eur Radiol · 2024-08-06

三组6个月时国际前列腺症状评分/生活质量评分改善及再干预率均无显著差异,不良事件无差异,结论为三种栓塞剂安全性和有效性相当。

要点

  • 三种栓塞颗粒(聚乙烯醇、三丙烯酰明胶微球、聚zen-F涂层水凝胶微球)行前列腺动脉栓塞术的疗效指标无显著差异。
  • 6个月时国际前列腺症状评分改善:聚乙烯醇组-10.7±7.9,三丙烯酰明胶微球组-10.4±7.3,聚zen-F涂层水凝胶微球组-10.4±7.0(p=0.987)。
  • 6个月后再干预率:聚乙烯醇组9%(5/53),三丙烯酰明胶微球组14%(7/50),聚zen-F涂层水凝胶微球组8%(4/50)(p=0.591)。

核心结论

  • 聚乙烯醇颗粒、三丙烯酰明胶微球和聚zen-F涂层水凝胶微球行前列腺动脉栓塞术治疗良性前列腺增生相关下尿路症状的安全性和有效性相当。

研究设计与样本

  • 单中心前瞻性队列研究,2019年至2023年纳入国际前列腺症状评分≥15和/或生活质量评分≥4的患者,按时间顺序分配栓塞剂:100-300 µm聚乙烯醇颗粒(n=53)、300-500 µm三丙烯酰明胶微球(n=50)、400 µm聚zen-F涂层水凝胶微球(n=50),基线及术后1、6个月评估。

关键影像表现/征象

  • 三组基线除年龄外无显著差异:聚乙烯醇组62.5岁,三丙烯酰明胶微球组66.1岁,聚zen-F涂层水凝胶微球组66.6岁(p=0.019)。
  • 无严重不良事件,组间轻微不良事件无差异。
  • 所有结局指标较基线显著改善,组间无显著差异。

诊断标准与关键数值

  • 6个月时国际前列腺症状评分/生活质量评分改善(均值±标准差):聚乙烯醇组-10.7±7.9/-2.2±1.7,三丙烯酰明胶微球组-10.4±7.3/-2.0±1.5,聚zen-F涂层水凝胶微球组-10.4±7.0/-2.2±1.6(p=0.987)。
  • 6个月后再干预率:聚乙烯醇组9%(5/53),三丙烯酰明胶微球组14%(7/50),聚zen-F涂层水凝胶微球组8%(4/50)(p=0.591)。
  • 纳入标准:国际前列腺症状评分≥15和/或生活质量评分≥4。

临床应用与阅片要点

  • 作者指出不同颗粒可互换用于前列腺动脉栓塞术。
  • 术后1个月和6个月需评估国际前列腺症状评分/生活质量评分、最大尿流率、排尿后残余尿量、前列腺体积及前列腺特异性抗原。
  • 需评估不良事件及前列腺再干预需求。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: Compare the safety and efficacy of polyvinyl alcohol particles (PVA) versus trisacryl gelatin microspheres (Embospheres) versus hydrogel microspheres coated with polyzene-F (Embozenes) for prostatic artery embolization (PAE) to treat patients with benign prostatic hyperplasia (BPH).

MATERIALS AND METHODS: A single-center prospective cohort study from 2019 to 2023, including patients with international prostate symptom score (IPSS) ≥ 15 and/or quality of life score (QoL) ≥ 4. Allocation to embolic agents was performed chronologically: 100-300 µm PVA (n = 53), followed by 300-500 µm Embospheres (n = 50), and finally, 400 µm Embozenes (n = 50). All patients were evaluated at baseline and at 1 and 6 months after PAE with IPSS/QoL; peak urinary flow rate, post-void residual volume, and prostate volume with ultrasound and prostate-specific antigen. Adverse events and the need for prostatic re-interventions were assessed.

RESULTS: There were no significant baseline differences between the three groups except for patient age (62.5 years PVA; 66.1 years Embospheres and 66.6 years Embozenes; p = 0.019). There were no major adverse events and no differences between groups regarding minor adverse events. All outcome measures improved significantly from baseline, with no significant differences between groups. Mean ± standard deviation IPSS/QoL improvement at 6 months: -10.7 ± 7.9/-2.2 ± 1.7 PVA; -10.4 ± 7.3/-2.0 ± 1.5 Embospheres; -10.4 ± 7.0/-2.2 ± 1.6 Embozenes (p = 0.987). Re-intervention rates after 6 months: 9% (n = 5/53) PVA; 14% (n = 7/50) Embospheres; 8% (n = 4/50) Embozenes (p = 0.591).

CONCLUSIONS: PAE with PVA particles, Embospheres, and Embozenes is equally safe and effective in treating BPH-related lower urinary tract symptoms.

CLINICAL RELEVANCE STATEMENT: This is the first prospective study showing equivalence between the most frequently used embolic agents for prostatic artery embolization.

KEY POINTS: Different particles can be used interchangeably for prostatic artery embolization. The improvements in measured metrics were the same between groups, with no differences in adverse events. The need for prostatic medication and re-intervention rates were the same at 1 and 6 months after embolization.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Bilhim T, Vasco Costa N, Torres D, et al. Comparing embolic particles for prostatic artery embolization to treat lower urinary tract symptoms in patients with benign prostatic hyperplasia. Eur Radiol. 2024. PMID: 39107451. doi:10.1007/s00330-024-10998-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。